OxaluRx is a preclinical company developing a small molecule, oral therapy to treat primary hyperoxaluria, a rare orphan metabolic disease. This rare form of hyperoxaluria is due exclusively to a genetic defect that causes a loss of specific enzymatic activity and the formation of kidney stones, leading to kidney damage and potentially failure. RiverVest is a founder of OxaluRx.